AstraZeneca says Imfinzi and Imdelltra improved survival
AstraZeneca said Imfinzi combined with Amgen’s Imdelltra significantly improved overall survival for extensive-stage small-cell lung cancer patients in a late-stage trial.
AstraZeneca said on Tuesday its cancer drug Imfinzi, when combined with Amgen's targeted immunotherapy Imdelltra, significantly improved overall survival in patients with extensive-stage small-cell lung cancer in a late-stage trial.